01911-A: Enhanced Hemangiosarcoma Therapy Using a Novel Combination of Drugs That Target Tumor Proliferation
Grant Status: Closed
Abstract
Hemangiosarcoma (HSA) is a common canine cancer of blood vessels for which there are few treatment options. In previous research Dr. Andersen showed two different drugs, a mitogen-activated protein kinase kinase (MEK) inhibitor and a receptor tyrosine kinase (RTK) inhibitor, were effective in slowing the growth of HSA tumor cells. There is emerging evidence from human oncology that multiple drug targets are necessary to prevent drug resistance in cancer. Dr. Andersen's current objective is to test his previously evaluated drugs in combination in a rodent model of canine cancer. He hypothesizes that tumor size will be smaller in mice treated with both drugs then each drug alone. He further hypothesizes the combination treatment will have a longer duration and decrease drug failure rate compared to each drug alone. The long-term objective is to use this treatment in the clinic to treat dogs with HSA.
Publication(s)
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.
